Confirm the FSHD phenotype before interpreting a genetic result
FSHD often causes facial weakness, scapular winging, difficulty raising the arms, asymmetric shoulder-girdle weakness and later involvement of trunk or leg muscles. Foot-drop weakness, hyperlordosis and pain can sometimes dominate the presentation. The DGM notes that clinical expression can vary widely even within the same family, so genetics should be interpreted together with a detailed neuromuscular examination.
- Facial weakness and eye-closure function
- Scapular winging and shoulder elevation
- Asymmetry between the two sides
- Trunk, abdominal and back weakness
- Foot dorsiflexion and fall history
- Pain, fatigue and current functional limits
FSHD1 and FSHD2 need specialized molecular interpretation
DGM guidance describes FSHD1 as usually involving contraction of the D4Z4 repeat region to 10 or fewer repeats on a permissive 4qA haplotype. FSHD2 more often involves D4Z4 hypomethylation, classically with a pathogenic SMCHD1 variant plus a permissive 4qA haplotype. Because this testing is more specialized than a routine sequencing panel, an inconclusive report should be reviewed by a neuromuscular genetics service rather than labelled negative from a standard gene panel alone.
Muscle biopsy is usually not the first way to confirm FSHD
DGM guidance states that the characteristic clinical picture can be supported by CK and EMG, but definitive confirmation is primarily human-genetic. A muscle biopsy is usually unnecessary for typical FSHD and can even show inflammatory changes that risk being misinterpreted as inflammatory myopathy. This is an important distinction before immunosuppressive treatment is considered for an uncertain diagnosis.
There is currently no approved disease-modifying medicine for FSHD
DGM states that there is currently no approved medication that cures FSHD or positively alters the disease course. Drug and RNA-based studies remain research. A German center can discuss study eligibility, but an experimental protocol should not be presented as established therapy or as a guaranteed route to slowing the disease.
Physiotherapy and individualized exercise are the core treatment pathway
Treatment focuses on maintaining function, avoiding secondary deconditioning and adapting activity to the patient's weakness pattern. DGM guidance supports regular physiotherapy and individualized aerobic endurance training, with care to avoid excessive overuse that worsens pain or fatigue. Occupational therapy and rehabilitation can help adapt work, self-care and household tasks.
- Shoulder and trunk function
- Gait and balance
- Stretching and range of motion
- Individualized aerobic conditioning
- Energy conservation and fatigue management
- Workplace and daily-living adaptations
Foot drop and mobility aids should be matched to fall risk
DGM guidance specifically notes foot-dorsiflexor weakness and fall risk. Orthopedic footwear, ankle-foot orthoses or other aids may improve safety in selected patients. Wheelchair or powered mobility can be used for longer distances or more advanced weakness without implying that a patient has lost all walking ability.
Scapular fixation is a selected option, not routine FSHD surgery
Scapular winging can severely limit arm elevation in some patients. DGM guidance notes that surgical scapular fixation (scapulopexy/scapulothoracic fixation) can be considered, but only rarely and after neuro-orthopedic assessment. The decision should account for remaining shoulder muscle strength, asymmetry, respiratory status, expected functional gain and the demands of postoperative rehabilitation.
Respiratory and sleep assessment is most relevant in more severe disease
Clinically significant respiratory weakness is uncommon in typical adult FSHD but can occur in severe or early-onset disease. DGM recommends respiratory therapy when respiratory muscles are affected and sleep-apnea or sleep-laboratory assessment when symptoms suggest nocturnal breathing problems. Non-invasive ventilation is reserved for selected patients with significant restrictive impairment.
Early-onset or severe FSHD can require hearing, eye and swallowing review
DGM guidance describes high-frequency sensorineural hearing loss and retinal vascular changes particularly in some early-onset cases, while severe disease can include dysphagia. These features are not present in every patient, so hearing, ophthalmology and swallowing testing should be symptom- and phenotype-directed rather than ordered as a universal package.
Cardiac disease is not usually the dominant FSHD complication
DGM notes that cardiomyopathy is generally not a typical FSHD manifestation, although arrhythmias or conduction abnormalities can occur rarely. Charité's cardiology service includes FSHD among muscular dystrophies it evaluates for cardiac involvement. Cardiac testing should therefore be guided by symptoms, prior findings, family context and specialist judgment rather than by assuming the DMD cardiac pathway applies unchanged to FSHD.
What to send for a German FSHD second opinion
The best review combines molecular results with a clear picture of current function and progression.
- Full FSHD molecular/genetic report, including D4Z4/4qA results when available
- SMCHD1 or methylation results if FSHD2 has been assessed
- Neuromuscular examination reports
- CK, EMG and muscle MRI results if already performed
- Photos or functional videos of scapular winging/arm elevation if the center requests them
- Physiotherapy, orthotic and mobility reports
- Pulmonary or sleep-study results in severe disease
- Hearing, ophthalmology or swallowing records when relevant
- Pain/fatigue treatments and current medication list
- A specific question: diagnosis confirmation, rehabilitation plan, orthotics, scapular surgery review or trial inquiry
Official sources
Sources last checked 2026-09-01. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- FSHD disease and treatment guidance — German Society for Muscular Diseases (DGM) ↗
- FSHD patient information – March 2024 — German Society for Muscular Diseases (DGM) ↗
- Heidelberg neuromuscular outpatient clinic — Heidelberg University Hospital ↗
- Charité cardiology – muscular dystrophies including FSHD — Charité – Universitätsmedizin Berlin ↗
- Freiburg Neuromuscular Center — University Medical Center Freiburg ↗